Spectral AI (MDAI)
NASDAQ:MDAI
MDAI Stock Chart & Stats
$1.58
-$0.15(-6.16%)
At close: 4:00 PM EST
$1.58
-$0.15(-6.16%)
Day’s Range― - ―
52-Week Range$1.10 - $3.21
Previous CloseN/A
Volume689.87K
Average Volume (3M)272.42K
Market Cap
$46.78M
Enterprise Value$41.48M
Total Cash (Recent Filing)$15.39M
Total Debt (Recent Filing)$10.09M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding31,823,895
10 Day Avg. Volume290,415
30 Day Avg. Volume272,420
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-6.58
Price to Sales (P/S)1.92
P/FCF Ratio-3.80
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit4.82
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$4.50Price Target Upside184.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$18.95M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMDAI reported revenue of $5.1M above estimates, indicating strong performance.
Regulatory ApprovalsMDAI submitted regulatory filings to the FDA for the Burn indication with US De Novo FDA clearance expected in the first half of next year.
Revenue PotentialMDAI unlocks significant revenue from BARDA upon clearance and has additional debt available as needed.
Bears Say
Earnings MissFor 2Q25, the company reported revenues of $5.1M and a net loss of $0.31 per diluted share, compared to consensus estimates revenues of $5.5M and a net loss of $0.07.
Guidance ReductionManagement lowered FY25 BARDA revenue guidance to ~$18.5M due to the timing of work and the government shutdown.
Revenue ShortfallMDAI reported revenue of $3.8M, which was below estimates of $5.0M.
Spectral AI News
MDAI FAQ
What was Spectral AI’s price range in the past 12 months?
Spectral AI lowest stock price was $1.10 and its highest was $3.21 in the past 12 months.
What is Spectral AI’s market cap?
Spectral AI’s market cap is $46.78M.
When is Spectral AI’s upcoming earnings report date?
Spectral AI’s upcoming earnings report date is May 12, 2026 which is in 40 days.
How were Spectral AI’s earnings last quarter?
Spectral AI released its earnings results on Mar 24, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.147.
Is Spectral AI overvalued?
According to Wall Street analysts Spectral AI’s price is currently Undervalued.
Does Spectral AI pay dividends?
Spectral AI does not currently pay dividends.
What is Spectral AI’s EPS estimate?
Spectral AI’s EPS estimate is -0.09.
How many shares outstanding does Spectral AI have?
Spectral AI has 31,823,895 shares outstanding.
What happened to Spectral AI’s price movement after its last earnings report?
Spectral AI reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Spectral AI?
Currently, no hedge funds are holding shares in MDAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spectral AI Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (184.81% Upside)
$4.50 (184.81% Upside)
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.06%
12-Months-Change
Fundamentals
Return on Equity
129.21%
Trailing 12-Months
Asset Growth
76.97%
Trailing 12-Months
Company Description
Spectral AI
Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.
MDAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive progression: key clinical and regulatory milestones (successful validation study, de novo submission and response) and a substantial BARDA funding acceleration materially de-risk near-term development. Financially, liquidity improved materially (cash tripled) and operating efficiencies reduced losses. However, there are meaningful near-term headwinds and uncertainties — reduced reimbursed R&D revenue as BARDA base-phase work winds down, continued full-year loss, dependence on BARDA and FDA timing, and revenue recognition/timing risks around BARDA-subsidized device placements. On balance the call emphasized tangible progress toward commercialization and improved financial footing while acknowledging execution and timing risks.View all MDAI earnings summariesMDAI Stock 12 Month Forecast
Average Price Target
$4.50
▲(184.81% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
8.85% Insiders
3.41% Mutual Funds
9.71% Other Institutional Investors
75.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---